Recombinant Human B7-2/CD86 Fc Chimera Avi-tag, CF

Name: Recombinant Human B7-2/CD86 Fc Chimera Avi-tag, CF
Brand: R&D Systems
SKU: AVI7625
Price: 592 USD
Availability: InStock

R&D Systems | Catalog # AVI7625

Submit a review

Product Documents

Biotinylated

100% Guarantee

Product Specifications
Scientific Data
Preparation & Storage
Calculators
Background
Product Documents
Specific Notices
Research Areas

Key Product Details

R&D Systems CHO-derived Recombinant Human B7-2/CD86 Fc Chimera Avi-tag (AVI7625)
Quality control testing to verify active proteins with lot specific assays by in-house scientists
All R&D Systems proteins are covered with a 100% guarantee

Source

CHO

Accession Number

AAH40261.1

Structure / Form

Disulfide-linked homodimer, Biotinylated vai Avi-tag

Conjugate

Biotin

Applications

Bioactivity

View all B7-2/CD86 Proteins and Enzymes »

Learn more about Avi-tag Biotinylated Proteins

Product Specifications

Source

Chinese Hamster Ovary cell line, CHO-derived human B7-2/CD86 protein

Human B7-2/CD86 (Leu26-Pro247) Accession # AAH40261.1	IEGRMD	Human IgG₁ (Pro100-Lys330)	Avi-tag
N-terminus			C-terminus

Purity

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Leu26

Predicted Molecular Mass

54 kDa

SDS-PAGE

87-101 kDa, under reducing conditions

Activity

The biotin to protein ratio is greater than 0.7 as determined by the HABA assay.

Measured by its binding ability in a functional ELISA.
When Recombinant Human CTLA-4 Fc Chimera (Catalog # 7268-CT) is immobilized at 0.25 μg/mL (100 μL/well), the concentration of Biotinylated Recombinant Human B7‑2/CD86 Fc Chimera Avi-tag (Catalog # AVI7625) that produces 50% of the optimal binding response is 5-30 ng/mL.

Scientific Data Images for Recombinant Human B7-2/CD86 Fc Chimera Avi-tag, CF

Recombinant Human B7-2/CD86 Fc Chimera Avi-tag Binding Activity

When Recombinant Human CTLA-4 Fc Chimera (Catalog # 7268-CT) is immobilized at 0.25 µg/mL, Recombinant Human B7-2/CD86 Fc Chimera Avi-tag (Catalog # AVI7625) binds with an ED₅₀ of 5-30 ng/mL.

Recombinant Human B7-2/CD86 Fc Chimera Avi-tag SDS-PAGE

2 μg/lane of Biotinylated Recombinant Human B7-2/CD86 Fc Chimera Avi-tag (Catalog # AVI7625) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 87-101 kDa and 170-200 kDa, respectively.

Formulation, Preparation, and Storage

AVI7625

Formulation	Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
Reconstitution	Reconstitute at 500 μg/mL in PBS.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Calculators

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Background: B7-2/CD86

B7-2, also known as CD86, B70, and ETC-1, is a 60-100 kDa variably glycosylated protein in the B7 family. B7 family members are transmembrane cell surface molecules that play important roles in immune activation and the maintenance of immune tolerance (1, 2). Mature human B7-2 consists of a 224 amino acid (aa) extracellular domain (ECD) with two Ig-like domains, a 21 aa transmembrane segment, and a 61 aa cytoplasmic tail (3, 4). Within the ECD, human B7-2 shares 59% aa sequence identity with mouse and rat B7-2. Alternative splicing of human B7-2 generates additional isoforms that lack both Ig-like domains or a region that includes the transmembrane segment. B7-2 is highly expressed on activated antigen presenting cells (APC), e.g. B cells, dendritic cells, and monocytes (4-7), as well as on vascular endothelial cells (8). B7-2 and the closely related B7-1/CD80 exhibit overlapping but distinct functional properties. Their binding to CD28, which is constitutively expressed on T cells, enhances T cell receptor signaling and also provides TCR-independent co-stimulation (3-5, 7, 9-11). B7-1 and B7-2 additionally bind the CD28-related protein, CTLA-4, which is up‑regulated and recruited to the immunological synapse (IS) at the onset of T cell activation (3-5, 7, 9, 10). CTLA-4 ligation inhibits the T cell response and supports regulatory T cell function (12). B7-2 is expressed earlier than B7-1 following APC activation (6), and both proteins bind with higher affinity to CTLA-4 than to CD28 (10). B7-2 promotes the stabilization of CD28 in the IS, while B7-1 is primarily responsible for promoting CTLA-4 recruitment and accumulation in the IS (13). The relative participation of B7-1 and B7-2 in T cell co-stimulation can also alter the Th1/Th2 bias of the immune response (14). Both B7-1 and B7-2 serve as cellular receptors for B species adenoviruses (15).